NEW YORK(GenomeWeb) – Cowen & Co. today upgraded shares of Fluidigm to Outperform, noting the company's strong base business and improvement in its DVS business. 

Also, William Blair upgraded Hologic shares to Outperform, citing changes to the firm's management. 

Cowen analyst Douglas Schenkel upgraded Fluidigm's shares from a previous Market Perform rating and increased the price target on the stock to $40 from $32. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.

The New York Times looks into medical research funding in the US and how the grant system might not be funding the best work.

US lawmakers proposed increasing the National Science Foundation budget, including its facilities account, Science reports.

In PNAS this week: effects of gene deletions on bacterial metabolic networks, genetic responses to sea star wasting disease, and more.